Clinical Research Directory
Browse clinical research sites, groups, and studies.
SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study
Sponsor: Yonsei University
Summary
This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). Using the nationwide database from the Korean National Health Insurance Service, the investigators will compare cardiovascular outcomes between patients treated with SGLT2 inhibitors and those treated with dipeptidyl peptidase-4 (DPP4) inhibitors after AMI. The study period includes patients diagnosed with AMI between September 2014 and June 2021, with follow-up data available through June 2022. The primary outcomes include major cardiovascular events (death, myocardial infarction, stroke) and bleeding events. This study will provide real-world evidence on the effectiveness and safety of SGLT2 inhibitors in routine clinical practice following AMI among patients with T2DM in Korea.
Official title: Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Population Cohort Study
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200000
Start Date
2014-09-01
Completion Date
2026-08-30
Last Updated
2025-09-30
Healthy Volunteers
No
Interventions
SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)
Exposure to SGLT2 inhibitors following AMI in patients with T2DM
DPP4 inhibitors
Exposure to DPP4 inhibitors following AMI in patients with T2DM
Locations (1)
Yongin Severance Hospital, Yonsei University Health System
Yongin, Gyeonggi-do, South Korea